Compositions and methods for modulation of Mcl-1 expression

Details Compositions and methods for modulation of Mcl-1 expression Compositions and methods for modulation of Mcl-1 expression

2007-03-16

2009-12-15

McGarry, Sean R (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024100, C536S024500, C435S006120, C435S375000, C435S377000

Reexamination Certificate

active

07632824

ABSTRACT:
Disclosed herein are compounds, compositions and methods for modulating the expression of Mcl-1 in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6001992 (1999-12-01), Ackermann et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6800750 (2004-10-01), Craig et al.
patent: 7250496 (2007-07-01), Bentwich
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: WO 94/29330 (1994-12-01), None
patent: WO 00/40595 (2000-07-01), None
patent: WO0177384 (2001-10-01), None
Aichberger et al., “Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.” Blood (2005) 105(8):3303-3311.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002,.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Derenne et al., “Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bel-XL is an essential survival protein of human myeloma cells” Blood (2002) 100(1):194-199.
Henson et al., “Herceptin Sensitizes ErbB2—Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression” Clin. Cancer Res. (2006) 12(3):845-853.
Leuenroth et al., “The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis” J. Leukoc. Biol. (2000) 68:158-166.
Liu et al., “Constitutively Actived Akt-1 Is Vital for the Survival of Human Monocyte-differentiated Macrophages: Role of Mcl-1, Independent of Nuclear Factor (NF)-kB, Bad, or Caspase Activation” J. Exp. Med. (2001) 194(2):113-126.
Michels et al., “Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage” Oncogene (2004) 23(28):4818-4827.
Moulding et al., “Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells” Blood (2000) 96:1756-1763.
New England Biolabs 1998/99 Catalog (cover page and pp. 121 and 284).
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Selzer et al., “Betulinic Acid-induced Mcl-1 Expression in Humna Melanoma—Mode of Action and Functional Significance” Mol. Med. (2002) 8(12):877-884.
Sieghart et al., “Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy” J. Hepatol, (2006) 44(1):151-157.
Sly et al., “Survival ofMycobacterium tuberculosisin Host Macrophages Involves Resistance to Apoptosis Dependent upon Induction of Antiapoptotic Bcl-2 Family Member Mcl-1” J. Immunol. (2003) 170(1):430-437.
Song et al., “Mcl-1 Regulates Survival and Sensitivity to Diverse Apoptotic Stimuli in Human Non-Small Cell Lung Cancer Cells” Cancer Biol. Ther. (2005) 4(3):267-276.
Thallinger et al., “Mcl-1 Antisense Therapy Chemosensitizes Human Melanoma in a SCID Mouse Xenotransplantation Model” J. Invest. Dermatol. (2003) 120(6):1081-1086.
Thallinger et al., “Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide” Clin. Cancer Res. (2004) 10:4185-4191.
Zhang et al., “Myeloid cell factor-1 is a critical survival factor for multiple myeloma” Blood (2002) 99(6):1885-1893.
International Search Report for PCT Application No. PCT/US2007/006706 dated Dec. 28, 2007.

Affiliated with

Also associated with

Rating

Compositions and methods for modulation of Mcl-1 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for modulation of Mcl-1 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulation of Mcl-1 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4052939